[print]   [close]
SANIONA
BIOTECHGATE BY VENTURE VALUATION
Latest up-date: 10 Apr 2024
GENERAL INFORMATION
 
Smedeland 26B
2600 Glostrup
Denmark
Contact person Mr. Thomas Feldthus, Co-Founder and Chief Executive Officer
Company main phone +45 (70) 705225
Website https://www.saniona.com
Founded (year) 2011
Source of foundation Independent foundation
No. of employees
worldwide
23
   
Corporate description / mission
Saniona is a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels. The company is advancing four product candidates including Tesomet™ and three ion channel modulators SAN711, SAN903 and SAN2219. Tesomet™ has progressed to mid-stage clinical trials for rare eating disorders. SAN711 has completed Phase 1 for neuropathic pain conditions. SAN903 is ready for Phase 1 for inflammatory and fibrotic disorders. SAN2219 is in preclinical development for epilepsy.
State of ownership Publicly listed on stock exchange
Headquarters HQ: Yes
IPO (year) 2014
Remarks on ownership / listings
Saniona was listed on AktieTorget on 22 April 2014 and on Nasdaq Firth North Premier on 19 May 2016.
On 30 May 2017, Nasdaq Stockholm's Listing Committee has approved that trading in the shares of Saniona is moved to the main market and consequently delisted from Nasdaq First North Premier.
CATEGORIZATION  
Main sector Biotechnology - Therapeutics and Diagnostics
Subsector(s)
  • Small molecules
Primary therapeutic area(s)
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Endocrine, nutritional and metabolic diseases / endocrinology
  • Diseases of the nervous system / neurology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
 
Business model
  • R&D
Customer segments
  • Large biotech & big pharma
  • Small biotech
  • Physicians / doctors
  • Hospitals
SUMMARY PRODUCTS / SERVICES / TECHNOLOGIES  
No. of Biotech Products Pre-clinical Phase I Phase II Phase III On the market
  3 1 2 n/a n/a
Description of products
Tesomet
SAN711
SAN903, etc.
Technology used
Ion channel drug discovery
FINANCING DETAILS
Fiscal year (end of) 2023
Revenues USD 1.64M
Net earnings USD -9.32M
Cash USD 3.01M
Interest bearing debt USD 8.38M
Market capitalization / valuation USD 18.36M
Money raised to date
(at least)		 USD 117.45M
No. of shares 111'238'000
 
Primary stock exchange Nasdaq Stockholm AB (SANION)
Financing details
n/a
COLLABORATIONS, CLIENTS & MARKETS  
Partnering strategy / collaborations
Medix
Novartis
Boehringer Ingelheim

 
ASK OUR LIFE SCIENCE EXPERT IN THE DANISH MARKET
Did you find what you were looking for? If not, feel free to contact us. We have in-depth knowledge of the biotech- and pharma industry, company pipelines and partnering opportunities in Medicon Valley.
 
Get in touch:
All fields are required.

Consultant: Niels Thun Andersen
Name:
Company:
E-Mail Address:
Subject:
Message:
CAPTCHA code

Please enter the above code into the field below.


 
 
© 2024 Venture Valuation  |  Impressum  |  Terms of Use & Privacy Policy  |  Print